|
Fluidigm Corporation is a public, American company engaged in the design, manufacture and sale of biological research equipment based on integrated fluidic circuit technology. In 2009, Fluidigm was described as "the world's leading manufacturer of microfluidic devices." Among the applications to which Fluidigm products are put to use are protein crystallization, genotyping, DNA analysis and PCR. ==Business model== Fluidigm's products leverage the capabilities of multilayer soft lithography to create microfluidic devices, specifically technology developed by one of the co-founders and branded "Integrated Fluidic Circuitry". Fluidigm is a public company traded on the NASDAQ stock exchange under the ticker symbol FLDM. Fluidigm has a number of academic partners whose engagement is aimed to provide a wow factor to exemplar product uses; partners include Wellcome Trust Sanger Institute, the Broad Institute, the Genome Institute of Singapore and Kyoto University. Among companies which include "integrated microfluidic technology" into their products, the only competitor which a market focus on biotechnology as of 2011 appeared to be RainDance Technologies. Going into 2015, the company is making an effort to infuse industrial design, aesthetic and customer centricity principles to help distinguish their products from those of competitors and generate a distinctive brand experience for users. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Fluidigm」の詳細全文を読む スポンサード リンク
|